Latest news with #StrongBuy
Yahoo
16 hours ago
- Business
- Yahoo
Is ESCO Technologies (ESE) Stock Outpacing Its Industrial Products Peers This Year?
Investors interested in Industrial Products stocks should always be looking to find the best-performing companies in the group. Is Esco Technologies (ESE) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Industrial Products peers, we might be able to answer that question. Esco Technologies is a member of the Industrial Products sector. This group includes 189 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Esco Technologies is currently sporting a Zacks Rank of #1 (Strong Buy). Within the past quarter, the Zacks Consensus Estimate for ESE's full-year earnings has moved 6.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger. Based on the most recent data, ESE has returned 45.2% so far this year. Meanwhile, stocks in the Industrial Products group have gained about 2.7% on average. This means that Esco Technologies is outperforming the sector as a whole this year. Another Industrial Products stock, which has outperformed the sector so far this year, is Kion Group (KIGRY). The stock has returned 65.5% year-to-date. The consensus estimate for Kion Group's current year EPS has increased 25.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Esco Technologies belongs to the Manufacturing - Electronics industry, a group that includes 17 individual stocks and currently sits at #53 in the Zacks Industry Rank. On average, stocks in this group have gained 2.6% this year, meaning that ESE is performing better in terms of year-to-date returns. On the other hand, Kion Group belongs to the Industrial Services industry. This 18-stock industry is currently ranked #144. The industry has moved -0.7% year to date. Investors with an interest in Industrial Products stocks should continue to track Esco Technologies and Kion Group. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ESCO Technologies Inc. (ESE) : Free Stock Analysis Report Kion Group (KIGRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
16 hours ago
- Business
- Yahoo
Is It Worth Investing in CyberArk (CYBR) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these Wall Street heavyweights have to say about CyberArk (CYBR) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. CyberArk currently has an average brokerage recommendation (ABR) of 1.13, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 32 brokerage firms. An ABR of 1.13 approximates between Strong Buy and Buy. Of the 32 recommendations that derive the current ABR, 29 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 90.6% and 6.3% of all recommendations. Check price target & stock forecast for CyberArk here>>> While the ABR calls for buying CyberArk, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential. Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations. In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement. With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision. In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures. Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide. In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research. Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns. There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices. Looking at the earnings estimate revisions for CyberArk, the Zacks Consensus Estimate for the current year has increased 41.9% over the past month to $3.81. Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for CyberArk. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, the Buy-equivalent ABR for CyberArk may serve as a useful guide for investors. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CyberArk Software Ltd. (CYBR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Here's Why Investors Should Bet on Copa Holdings Stock Now
Copa Holdings CPA is benefiting from its robust expansion and modernization efforts, boosting the company's operational efficiency. The shareholder-friendly initiatives are also encouraging. Owing to these tailwinds, CPA shares have performed impressively on the bourse. If you have not taken advantage of its share price appreciation yet, it's time to do so. CPA's Northward Earnings Estimate Revision: The Zacks Consensus Estimate for earnings per share has been revised upward by 6.4% over the past 60 days for the current year. For 2026, the consensus mark for earnings per share has moved 4.9% north in the same time frame. The favorable estimate revisions indicate brokers' confidence in the stock. Image Source: Zacks Investment Research Robust Price Performance: A look at the company's price trend reveals that its shares have risen 19.9% year to date, surpassing the Zacks Transportation – Airline industry's 7.1% fall. Image Source: Zacks Investment Research Positive Earnings Surprise History: Copa Holdings has an encouraging earnings surprise history. The company's earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 5.5%. Solid Zacks Rank: CPA currently sports a Zacks Rank #1 (Strong Buy). Bullish Industry Rank: The industry to which CPA belongs currently has a Zacks Industry Rank of 48 (out of 244). Such a favorable rank places it in the top 20% of Zacks show that 50% of a stock price movement is directly related to the performance of the industry group to which it belongs. A mediocre stock within a strong group is likely to outperform a robust stock in a weak industry. Reckoning the industry's performance becomes imperative. Growth Factors: Copa Holdings continues to drive long-term growth and modernization, ending the first quarter of 2025 with a streamlined fleet of 112 Boeing 737 aircraft. This uniform fleet supports cost-efficient operations and simplified maintenance. Strengthening its future plans, Copa exercised options for six additional 737 MAX-8s for delivery in 2028, raising its firm order book to 57. Operationally, the airline led the industry with a 90.8% on-time performance and a 99.9% flight completion rate, underscoring its focus on efficiency and reliability. Copa's commitment to delivering shareholder value remains strong. In 2024, the company repurchased $87 million in shares under its $200 million share buyback program, representing approximately 2% of total outstanding shares at year-end. In addition, Copa's board approved a quarterly dividend of $1.61 per share for 2025, payable on June 13 to shareholders of record as of May 30. Through share repurchases and consistent dividends, Copa continues to prioritize long-term value for its investors. Investors interested in the Transportation sector may also consider SkyWest SKYW and Air Lease AL. SKYW currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. SKYW has an expected earnings growth rate of 19.4% for the current year. The company has an impressive earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 17.1%. Shares of SKYW have risen 21.1% year to date. AL currently carries a Zacks Rank #2. The company has a mixed earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, delivering an average beat of 5.2%. Shares of AL have rallied 18.5% year to date. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Copa Holdings, S.A. (CPA) : Free Stock Analysis Report Air Lease Corporation (AL) : Free Stock Analysis Report SkyWest, Inc. (SKYW) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
2 days ago
- Business
- Globe and Mail
Here's Why Investors Should Bet on Copa Holdings Stock Now
Copa Holdings CPA is benefiting from its robust expansion and modernization efforts, boosting the company's operational efficiency. The shareholder-friendly initiatives are also encouraging. Owing to these tailwinds, CPA shares have performed impressively on the bourse. If you have not taken advantage of its share price appreciation yet, it's time to do so. Upsides for CPA CPA's Northward Earnings Estimate Revision: The Zacks Consensus Estimate for earnings per share has been revised upward by 6.4% over the past 60 days for the current year. For 2026, the consensus mark for earnings per share has moved 4.9% north in the same time frame. The favorable estimate revisions indicate brokers' confidence in the stock. Robust Price Performance: A look at the company's price trend reveals that its shares have risen 19.9% year to date, surpassing the Zacks Transportation – Airline industry's 7.1% fall. Positive Earnings Surprise History: Copa Holdings has an encouraging earnings surprise history. The company's earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 5.5%. Solid Zacks Rank: CPA currently sports a Zacks Rank #1 (Strong Buy). Bullish Industry Rank: The industry to which CPA belongs currently has a Zacks Industry Rank of 48 (out of 244). Such a favorable rank places it in the top 20% of Zacks show that 50% of a stock price movement is directly related to the performance of the industry group to which it belongs. A mediocre stock within a strong group is likely to outperform a robust stock in a weak industry. Reckoning the industry's performance becomes imperative. Growth Factors: Copa Holdings continues to drive long-term growth and modernization, ending the first quarter of 2025 with a streamlined fleet of 112 Boeing 737 aircraft. This uniform fleet supports cost-efficient operations and simplified maintenance. Strengthening its future plans, Copa exercised options for six additional 737 MAX-8s for delivery in 2028, raising its firm order book to 57. Operationally, the airline led the industry with a 90.8% on-time performance and a 99.9% flight completion rate, underscoring its focus on efficiency and reliability. Copa's commitment to delivering shareholder value remains strong. In 2024, the company repurchased $87 million in shares under its $200 million share buyback program, representing approximately 2% of total outstanding shares at year-end. In addition, Copa's board approved a quarterly dividend of $1.61 per share for 2025, payable on June 13 to shareholders of record as of May 30. Through share repurchases and consistent dividends, Copa continues to prioritize long-term value for its investors. Other Stocks to Consider Investors interested in the Transportation sector may also consider SkyWest SKYW and Air Lease AL. SKYW currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. SKYW has an expected earnings growth rate of 19.4% for the current year. The company has an impressive earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 17.1%. Shares of SKYW have risen 21.1% year to date. AL currently carries a Zacks Rank #2. The company has a mixed earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, delivering an average beat of 5.2%. Shares of AL have rallied 18.5% year to date. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Copa Holdings, S.A. (CPA): Free Stock Analysis Report Air Lease Corporation (AL): Free Stock Analysis Report SkyWest, Inc. (SKYW): Free Stock Analysis Report
Yahoo
6 days ago
- Business
- Yahoo
Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy' Penny Stocks
Big names may rule the headlines, but many of the market's future stars begin as under-the-radar underdogs. While Wall Street focuses on the trillion-dollar club – think the 'Magnificent 7' – some of the most compelling opportunities are tucked away in the bargain bin, trading for $5 or less. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter These low-priced stocks – known as penny stocks – often operate in high-growth corners of the market, and when the right catalyst hits, whether a breakthrough innovation or a disruptive product, they can deliver explosive gains. That said, not every penny stock is a diamond in the rough. Some linger at the bottom for good reason, dragged down by shaky fundamentals or challenges that may be too big to overcome. So, how do you spot the ones ready to take off? That's where Wall Street's analysts come into play. Using TipRanks' database, we've zeroed in on two standout penny stocks earning high marks from analysts. Both boast a 'Strong Buy' consensus rating and substantial upside potential – with one eyeing a nearly 590% surge. Let's take a closer look and find out what the optimism is all about. Skye Bioscience (SKYE) We'll start with Skye Bioscience, a biopharmaceutical researcher developing new treatments for metabolic disorders, with a particular focus on obesity. This is a fertile area for an innovative biotech firm – the global anti-obesity drug market is projected to grow from $12.8 billion in 2025 to $104.9 billion by 2035, reflecting a 21.1% CAGR over the forecast period. Beyond its prevalence, obesity contributes to a host of physical and mental health complications, creating a need for effective therapies. To meet this need, Skye is taking a novel approach to weight loss by targeting the CB1 pathway through selective inhibition. Its lead candidate, nimacimab, is a peripherally restricted CB1 inhibitor, specifically designed to sidestep the central nervous system side effects that limited earlier CB1-targeting drugs. Now in a Phase 2a clinical trial, CBeyond, nimacimab is approaching a key catalyst: the release of topline data expected in late Q3 or early Q4 2025. In earlier testing at the preclinical and Phase 1 stages, nimacimab demonstrated encouraging results. In an April update, Skye reported that in a mouse model, combining nimacimab with tirzepatide (a dual GLP-1/GIP agonist) resulted in over 30% weight loss after 25 days. Nimacimab alone produced a 23.5% reduction, comparable to monotherapies with tirzepatide or monpelabant. Supporting its safety profile, multiple reviews by the Data Safety Monitoring Committee have been completed with no concerns raised to date. Looking ahead to future clinical development and potential commercialization, Skye has partnered with Arecor Therapeutics to explore a new formulation of nimacimab. Under the agreement, Skye will fund the development using Arecor's proprietary formulation platform and holds an option to license the resulting formulation, including associated intellectual property and commercialization rights. With SKYE trading at $2.16, JMP analyst Jonathan Wolleben sees a big opportunity brewing – especially with a topline data readout just around the corner. 'We continue to like nimacimab's position in the CB1 inhibitor pipeline as a truly peripherally restricted inhibitor, and we view the rapid and over-enrollment of CBeyond as reflective of the high patient enthusiasm for the differentiated mechanism in the obesity pipeline. We think CBeyond is well-designed to answer key safety and efficacy questions, and we like that the DSMC reviews have not raised any concerns to date. Given the history of mechanism, safety will be top of mind for investors. Recall that SKYE saw no neuropsychiatric side effects in its prior Phase 1 and no accumulation in the CNS or brain in non-human primates… We'll see 26-week weight loss data from SKYE's Phase 2a trial in late 3Q/early 4Q where the study is powered to detect an 8% pbo-adj. difference which we would view as a win and should drive shares higher,' Wolleben opined. Backing his bullish case, Wolleben rates SKYE a Buy with a $16 price target, implying a massive one-year upside potential of 594%. (To watch Wolleben's track record, click here) The overall view of SKYE is even more bullish than that. The stock's Strong Buy consensus rating is unanimous, based on 6 positive analyst reviews, and the $17.20 average price target suggests a whopping 696% premium over the next 12 months. (See SKYE stock update) PolyPid (PYPD) Surgery is difficult for patients, even under the best conditions, with infection, inflammation, and pain among the potential post-operative complications. PolyPid, a clinical-stage biopharmaceutical company, is working to address these issues through improved medication delivery. The company has developed a proprietary drug delivery platform called PLEX (polymer-lipid encapsulation matrix), designed to provide targeted, localized, and sustained release of post-operative medications. This layered system – built from alternating polymers and lipids – can deliver a wide range of therapeutic agents, including small molecules, proteins, peptides, and nucleic acids. PLEX is engineered to maintain drug potency and minimize toxicity, enabling controlled release over extended periods, potentially lasting several months. Leveraging this platform, PolyPid developed its lead product candidate, D-PLEX100, which has been evaluated in two Phase 3 clinical trials – SHIELD I and SHIELD II – focused on preventing surgical site infections following abdominal colorectal procedures. While the SHIELD I study did not meet its primary endpoint, PolyPid announced positive topline results from SHIELD II earlier this month. The trial achieved both its primary and key secondary endpoints, demonstrating statistically significant benefits in 798 patients undergoing large abdominal surgeries. With these results, the company is preparing for a potential New Drug Application (NDA) submission in early 2026 and views the data as a catalyst for advancing global partnership discussions. To support its next steps, the company also secured up to $26.7 million in funding through the exercise of outstanding warrants, extending its cash runway beyond the expected FDA approval window for D-PLEX100. Roth Capital analyst Boobalan Pachaiyappan views the SHIELD II results as a turning point – not only confirming clinical efficacy but also laying out a compelling path toward regulatory approval and a sizable market opportunity for D-PLEX100. 'D-PLEX100 delivered efficacy across the board on all secondary endpoints… Although a comprehensive safety data analysis was not presented, given that only top-line data are available, the lack of safety signals suggests that D-PLEX100 is safe and tolerable, exhibiting a profile consistent with previous studies, and is suitable for treating SSI patients… We expect D-PLEX100 FDA approval in 2H26, with the initial launch in 2027 focusing on colorectal surgeries (partner: TBD) and the EU/U.K. launch in 2028 (partner: ADVANZ Pharma; private), with subsequent launches within the broader abdominal procedures category (~4.5M surgeries) in the following years… Our models suggest >$800M in peak sales in 2035, with PYPD revenue >$200M (net royalty rate: 25%),' Pachaiyappan wrote. Pachaiyappan quantifies his positive stance with a Buy rating on PYPD and a $9 price target that points toward a one-year gain of 174%. (To watch Pachaiyappan's track record, click here) Overall, there are 5 recent analyst reviews on record for PYPD shares, and the 4-to-1 split, favoring Buy over Hold, gives the stock its Strong Buy consensus rating. The shares are priced at $3.28, and their $11.50 average target price suggests an upside of 250% on the one-year horizon. (See PYPD stock forecast) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Sign in to access your portfolio
